Review ArticlesCardiotoxicity of Cancer TherapiesMondal, Pratik MD; Jain, Diwakar MD; Aronow, Wilbert S. MD; Frishman, William H. MDAuthor Information From the Division of Cardiology and the Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY. Disclosure: The authors have no conflicts of interest to report. Correspondence: Wilbert S. Aronow, MD, FACC, FAHA, Cardiology Division, Westchester Medical Center, Macy Pavilion, Room 141, Valhalla, NY 10595. E-mail: [email protected]. Cardiology in Review: September/October 2019 - Volume 27 - Issue 5 - p 230-235 doi: 10.1097/CRD.0000000000000239 Buy Metrics Abstract Cardiotoxicity is a known complication of many cancer therapies. While the cardiotoxicity of established agents such as anthracyclines, antimetabolites, and alkylating agents is well known, it is important to realize that newer anticancer therapies such as tyrosine kinase inhibitors, angiogenesis inhibitors, and checkpoint inhibitors are also associated with significant adverse cardiovascular effects. Echocardiography, magnetic resonance imaging, and radionuclide imaging have been used to identify these complications early and prevent further consequences. We will discuss the different classes of cancer therapeutic agents that cause cardiotoxicity, the mechanisms that lead to these effects, and strategies that can be used to prevent the cardiac morbidity and mortality associated with their use. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.